Weight loss biotech plans IPO as demand builds for anti-obesity treatments
Aardvark Therapeutics’ drug has been shown in trials to suppress cravings in patients with rare genetic form of obesity
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Eating Disorders & Weight Management | Genetics | Obesity | Pharmaceuticals | Weight Loss